Product Features

  • All-Fect
  • Prime-Fect
  • Leu-Fect A & B
  • Trans-Booster
  • mRNA-Fect
  • CRISP-Fect

All-Fect

Designed as a siRNA pDNA transfection reagent it can be used for either siRNA knockdown, plasmid DNA transformation or siRNA pDNA co-delivery. It is particularly suitable for mesenchymal stem cells from cord blood and bone marrow, and highly differentiated cells such as smooth muscle cells, and endothelial cells.
 
Download Information All-Fect Brochure

Benefits of the reagent :

High transfection efficiency

Provides 2 to 3-fold higher efficacy in the presences of serum

Simple Protocol

No need to change tissue culture medium during transfection

Lower Toxicity

Less toxic compared to commercial transfection reagents, leading to better retention of normal cellular physiology

References:

Typical performance of All-Fect for transfecting cord-blood derived mesenchymal stem cells with a GFP plasmid. The study compared the performance of All-Fect against a leading lipofection reagent under conditions optimized for each reagent. The extent of transgene expression was quantitated by flow cytometry, based on the extent of EGFP expression in arbitrary units. Typical fluorescent micrographs showing GFP expression after transfection are provided on the top.

Prime-Fect

This product is designed for transfection of primary cells with plasmid DNA. Prime-Fect has been tailored for attachment dependant cell plasmid DNA delivery, but also has been effective in siRNA delivery to attachment dependant cells and plasmid transfection of non-attachment dependant cells.
 
Download Information Prime-Fect Brochure

Benefits of the reagent :

High transfection efficiency

Provides 2 to 3-fold higher efficacy in the presences of serum

Simple Protocol

No need to change tissue culture medium during transfection

Lower Toxicity

Less toxic compared to lipofection reagents, leading to minimal alteration of cell physiology

References:

Transfecting bone marrow stromal cells with Prime-Fect. GFP expression was induced with a plasmid and analyzed by fluorescent microscopy 2 days after transfection. Cell-associated DNA is visualized with a red label (A). Transfecting breast cancer MDA-MB-231 and MCF-7 cells with siRNA using Prime-Fect. The expression levels of two target genes were analyzed by qPCR after delivery of control (scrambled) and gene-specific siRNAs (2 days after transfection) (B). Transfecting umbilical cord-derived mesenchymal stem cells with Prime-Fect. GFP expression was induced with a plasmid DNA and analyzed by fluorescent microscopy 2 days after transfection. (C) A leading polymeric transfection reagent and (D) Prime-Fect.>

Leu-Feact A and Leu-Fect B

These products are designed for transfection of attachment-independent (suspension growing) cells and are specifically tailored for siRNA delivery. We offer two different formulations (Leu-Fect A and Leu Fect B) that are effective in different types of attachment-independent cells. We recommend the users to test the efficacy of both reagents in their particular cell type and choose the right formulation for long-term use.
 
Download Information Leu-Fect A Brochure
Leu-Fect B Brochure

Benefits of the reagent :

High transfection efficiency

Provides 2 to 3-fold higher efficacy in the presences of serum

Simple Protocol

No need to change tissue culture medium during transfection

Lower Toxicity

Less toxic compared to lipofection reagents, leading to minimal alteration of cell physiology

References:

Uptake of Leu-Fect/FAM-siRNA complexes in K562 cells in vitro (A) and in vivo K562 tumors (B). Typical performance of Leu-Fect for transfecting K562 chronic myeloid leukemia (CML) cells with a specific siRNA against Bcr-Abl. The study compared the performance of Leu-Fect against a leading lipofection reagent and branched PEI (PEI25; 25 kDa) under conditions optimized for each reagent. The extent of gene silencing was quantitated by qPCR (C). The functional outcome, in the form of inhibition of cell growth, was assessed by the MTT Assay and expressed relative to non-treated cells (D).

Trans-Booster

This product is designed to enhance the transfection efficiency of plasmid DNA in attachment dependent and suspension-growing cells. Enhancing the transfection efficiency allows production of greater amount of protein for a desired effect, as well as allowing lower amount of DNA and transfection reagent to be used. This reagent could be also effective with other nucleic acids (siRNA, microRNA) depending on the cell type.
 
Download Infromation Trans-Booster Brochure

Benefits of the reagent :

High transfection efficiency

Provides 2 to 3-fold higher efficacy in the presences of usual transfection reagent

Simple Protocol

No need to change tissue culture medium during transfection

Lower Toxicity

Less toxic compared to lipofection and polymeric reagents, leading to better protein yields from the transfected cells

Stability

Long term stability at room temperature

Typical performance of Trans-Booster reagent for transfecting suspension growing Jurkat cells (top). Transfections with a GFP plasmid and a GFP mRNA are conducted in Jurkat cells with and without Trans-Booster in the transfection formulation. A leading lipofection reagent was compared to the All-Fect transfection reagent from RJH Biosciences in this study. The extent of transgene expression was quantitated by flow cytometry and summarized as the mean GFP fluorescence in arbitrary units. Note that for both mRNA and plasmid DNA based GFP expression, Trans-Booster gave a significant increase in transfection efficiency.

mRNA-Fect

This product is designed for mRNA delivery of both attachment-dependent and attachment-independent (suspension growing) cells. mRNA-Fect has also been tested and found effective for plasmid DNA and siRNA delivery in certain cell types. We recommend the users to test the efficacy of the reagent in their particular cell type and choose the right formulation for long-term use.
 
Download Information mRNA-Fect Brochure

Benefits of the reagent :

High transfection efficiency

Provides 2 to 7-fold higher efficacy in the presences of serum compared with lipofection reagents

Simple Protocol

No need to change tissue culture medium during transfection

Lower Toxicity

Less toxic compared to lipofection reagents, leading to minimal alteration of cell physiology

Transfection of mRNA with mRNA-Fect in (A) attachment-dependent MCF-7, MDA-MB-436 and MDA-MB-231 cells and (B) suspension-growing K562 and THP-1 cells. An mRNA coding for a reporter protein (Green Fluorescent Protein, GFP) was used to assess the efficiency of mRNA expression. Typical GFP expression levels were visualized under fluorescent microscopy (top pictures). The expression levels were quantitated by flow cytometry 72 hours after transfection and summarized as the percentage of cells positive for GFP (bottom graphs). For comparison, a leading lipofection reagent was used according to the manufacturer’s instructions.

CRISP-Fect

This product is designed for CRISPR-Cas9 RNP delivery to various attachment dependent and suspension cell types. Please click on the “view product” link below for information and example data on applied cell types. We recommend that users test the efficacy of the reagent in their particular cell type and choose the right formulation for long-term use. General optimization protocols can be found here. Applied cell types for all of our commercial reagents can also be found on the resources page. Specific protocols can be found in the following brochure below.
 
Download Information CRISP-Fect brochure

Benefits of the reagent :

High transfection efficiency

Provides 2 to 7-fold higher efficacy in the presences of serum compared with lipofection reagents

Simple Protocol

No need to change tissue culture medium during transfection

Lower Toxicity

Less toxic compared to lipofection reagents, leading to minimal alteration of cell physiology

References:

Figure 1. Left. Transfection of Jurkat T-cells and breast cancer MDA-MB-436 cells using CRISP-Fect. sgRNA/Cas9 complexes (RNP) were formulated with indicated transfection reagents and added to the cells for 24 hours. RNP uptake was followed by using FITC-labeled Cas9. The results are summarized as arbitrary fluorescence units, indicating the average amount of RNPs delivered per cell. Right. Transfection of Jurkat T-cells with RNPs formulated at different ratios of Cas9/sgRNA using CRISP-Fect. Lipofectamine 2000 and jetOptimus was used as commercial reference reagents in these studies.